Corporate Board Profile
Tech Score: 33/100
3 mention(s) identify DR. BASSIL I. DAHIYAT as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| Xencor Inc | 2014-04-29 | Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. Dr. Dahiyat was named one of 2003’s Top 100 Young Innovators by MIT’s Technology Review magazine for his work on protein design and its development for therapeutic applications. | Dr. Dahiyat has a Ph.D. in Chemistry and degrees in Biomedical Engineering, with recognition for work on protein design and technology development, indicating strong technical and scientific expertise that likely includes programming or related skills. |
| Xencor Inc | 2016-04-27 | Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. We believe Dr. Dahiyat's experience in the pharmaceutical industry and as one of our founders qualifies him to serve on our Board of Directors. | Dr. Dahiyat has a Ph.D. in Chemistry and degrees in Biomedical Engineering, and was recognized for work on protein design and technology development, indicating strong technical and scientific expertise which likely includes programming or software-related skills. |
| Xencor Inc | 2024-04-24 | Dr. Dahiyat holds a Ph.D. in chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in biomedical engineering from Johns Hopkins University. He was named one of 2003’s Top 100 Young Innovators by MIT’s Technology Review magazine for his work on protein design and its development for therapeutic applications. | Dr. Dahiyat holds a Ph.D. in chemistry and has been recognized for his work on protein design and its development for therapeutic applications, indicating a strong technical and scientific background likely including programming or computational skills. |
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-29 | Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. Dr. Dahiyat was named one of 2003’s Top 100 Young Innovators by MIT’s Technology Review magazine for his work on protein design and its development for therapeutic applications. |
| 2015-04-24 | Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. |
| 2016-04-27 | Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. We believe Dr. Dahiyat's experience in the pharmaceutical industry and as one of our founders qualifies him to serve on our Board of Directors. |
| 2017-05-01 | Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. |
| 2018-04-27 | Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. |
| 2019-04-30 | Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. |
| 2020-04-29 | Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. |
| 2023-04-26 | Dr. Dahiyat holds a Ph.D. in chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in biomedical engineering from Johns Hopkins University. |
| 2024-04-24 | Dr. Dahiyat holds a Ph.D. in chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in biomedical engineering from Johns Hopkins University. He was named one of 2003’s Top 100 Young Innovators by MIT’s Technology Review magazine for his work on protein design and its development for therapeutic applications. |
Data sourced from SEC filings. Last updated: 2026-03-05